OctoPlus' licensee Biolex to present final results of Locteron Phase IIb study at EASL conference
(Thomson Reuters ONE) -
Presentations will highlight strong antiviral activity and SVR rates together
with significant reductions in flu-like adverse events and reduced rates of
depression
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO) announces that two
abstracts by its licensee Biolex Therapeutics have been accepted for
presentation on 31 March at the 46th Annual Meeting of the European Association
for the Study of the Liver (EASL) in Berlin, Germany.
The titles of the abstracts are included below and the complete abstracts are
now available on the EASL website atwww2.kenes.com/liver-congress.
* SVRfor controlled-release interferon alpha-2b (CR2b) + ribavirin compared to
PEGylated interferon alpha-2b (PEG2b) + ribavirin in treatment-naïve
genotype-1 (G1) hepatitis C: final results from SELECT-2
* Timing and frequency of depression during HCV-treatment with controlled-
release-IFNa2b (CR2b) vs. PEGylated-IFNa2b (PEG2b): results from SELECT-2, a
randomized-open-label-72-week-comparison in 116 treatment-naïve patients
with genotype-1 HCV
For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071, or
send an e-mail to Investor Relations at IR(at)octoplus.nl.
About Locteron
Locteron is a controlled release formulation of interferon alpha for the
treatment of chronic hepatitis C. Locteron combines OctoPlus' controlled release
drug delivery technology PolyActive® with Biolex' interferon alpha and is the
most advanced product in clinical development incorporating one of OctoPlus'
proprietary drug delivery technologies. OctoPlus licensed its commercial rights
to Locteron exclusively to Biolex in October 2008.
Locteron is an investigational therapeutic candidate and has not been approved
for sale by the United States Food and Drug Administration or by any
international regulatory agency.
About OctoPlus
OctoPlus is a drug delivery service company committed to the creation of
improved pharmaceutical products that are based on OctoPlus' proprietary drug
delivery technologies and have fewer side effects, improved patient convenience
and a better efficacy/safety balance than existing therapies. OctoPlus focuses
on the development of long-acting, controlled release versions of known protein
therapeutics, other drugs, and vaccines on behalf of its clients.
The clinically most advanced product incorporating our technology is Biolex
Therapeutics' lead product Locteron®, a controlled release formulation of
interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed
Locteron exclusively to Biolex in October 2008. Locteron is being manufactured
for Biolex by OctoPlus and has recently completed Phase IIb clinical studies
with superior clinical data versus current treatment.
In addition, OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the pharmaceutical and
biotechnology industries, with a focus on difficult-to-formulate active
pharmaceutical ingredients.
OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO.
For more information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of OctoPlus and the industry in
which it operates. These statements are based on OctoPlus' current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate", "predict",
"estimate", "project", "plan", "may", "should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
Click here for the press release in PDF format:
http://hugin.info/137076/R/1495527/431585.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: OctoPlus N.V. via Thomson Reuters ONE
[HUG#1495527]
Unternehmensinformation / Kurzprofil:
Datum: 10.03.2011 - 07:45 Uhr
Sprache: Deutsch
News-ID 52307
Anzahl Zeichen: 5416
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 213 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OctoPlus' licensee Biolex to present final results of Locteron Phase IIb study at EASL conference"
steht unter der journalistisch-redaktionellen Verantwortung von
OctoPlus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
